Navigation Links
Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
Date:11/6/2008

Supports safety of AHCC for cancer patients undergoing chemotherapy

PURCHASE, N.Y., Nov. 6 /PRNewswire/ -- A recently published study in the Journal of the Society for Integrative Oncology (Vol. 6, No. 3 (Summer), 2008: pp 105-109) by researchers at the University of Texas M.D. Anderson Cancer Center with the support of researchers from Amino Up Chemical Company in Sapporo, Japan has demonstrated that AHCC (Active Hexose Correlated Compound) can be safely used in combination with most chemotherapy agents. AHCC is a leading and commonly utilized dietary supplement for immune enhancement and cancer. The study was designed to determine on how AHCC interacts with select chemotherapy agents. As most chemotherapy agents undergo metabolism in the body through the CYP450 (Cytochrome P-450) pathway, this parameter was investigated in combination with four isoenzymes (3A4, 2C8, 2C9 and 2D6). This was followed by an evaluation of AHCC by including it as a substrate of these same isoenzymes.

The results of this in vitro metabolism study indicated that AHCC is not an inhibitor of the major CYP450 isoenzyme pathways. Therefore, AHCC is safe and unlikely to result in increased toxicity when used in combination with commonly used chemotherapeutic agents such as Cyclophosphamide, Ifosfamide, Paclitaxel, Docetaxel, Irinotecan, Vincristine, Interferon and Imatinib. It was demonstrated, that AHCC may have the potential for induce metabolism of drugs metabolized via the CYP450 2D6 pathway. Fortunately, the CYP450 2D6 is not a predominant pathway for metabolism of the most commonly used chemotherapy agents.

"Research shows that AHCC benefits cancer patients with its antitumor effects as well as its potential restorative effects on natural killer cells, macrophages and cytokines after anticancer chemotherapy," said Judith Smith, Pharm.D., BCOP,FCCP, FISOPP, Department of Gynecologic Oncology, Division of Surgery with The University of Texas M.D. Anderson Cancer Center. "The safety of AHCC in combination with anti-cancer agents needed evaluation and this study confirms that AHCC is safe to administer with most chemotherapy agents."

In addition to this study, research completed at other institutions with AHCC has shown that it activates important immune white blood cells including macrophages, Natural Killer (NK) cells and Lymphokine-Activated Killer (LAK) cells. AHCC also induces the production of cytokines that serve as chemical messengers between cells. AHCC has been the subject of over 80 research studies worldwide including studies completed at Harvard University's Faulkner Hospital, Yale University and Columbia University Medical Center.

What is AHCC (Active Hexose Correlated Compound)?

AHCC is derived from the hybridization of several subspecies of medicinal mushroom, cultivated in Japan and then produced from a unique manufacturing process. AHCC is the leading immune-enhancing supplement in Japan and is utilized by over 700 hospitals and healthcare facilities worldwide as a standard preventative supplement for incoming patients to help reduce the risk of hospital infections as well as supporting the body's fight against the formation of abnormal cells.*

AHCC is manufactured by Amino Up Chemical Company in Sapporo, Japan and is distributed in the United States by Maypro Industries. Maypro sells AHCC to a number of leading supplement companies including Quality of Life Laboratories, a subsidiary of Maypro.

The AHCC Research Association was founded in 1986 to promote further study. Each year since 1994, over 300 medical doctors and researchers have gathered in Sapporo, Japan for the AHCC Research Association Symposium to share and discuss the latest developments.

To learn more about AHCC, visit the AHCC Research Association Web site at http://www.ahccresearch.com.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or mitigate disease.


'/>"/>
SOURCE AHCC Research Association
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
2. New Study Provides Key Findings for Biopharma Product Launch Evaluation
3. Top-Line Preliminary Data From Phase II/III Study of Cortheras Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008
4. DermTech and Rady Childrens Hospital-San Diego, Initiate Study to Understand Effects of Vitamin D as a Treatment for Atopic Dermatitis in Children and Young Adults
5. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
6. Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
7. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
8. Large-scale genetic study sheds new light on lung cancer
9. PARI Respiratory to Present New Study Comparing Nebulizers Delivering Budesonide at CHEST 2008
10. Independent Study Reveals SYNVISC(R) Offers Longer Knee Pain Relief and Greater Patient Satisfaction for Those Suffering from Osteoarthritis of the Knee
11. Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)... ... 27, 2016 , ... Parallel 6 , the leading software as a ... Reach Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine ... team. , Using the CONSULT module, patients and physicians can schedule a face to ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
Breaking Biology Technology:
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
Breaking Biology News(10 mins):